Monocyte chemoattractant protein-1 and the kidney

Curr Opin Nephrol Hypertens. 2016 Jan;25(1):42-9. doi: 10.1097/MNH.0000000000000186.


Purpose of review: Recently, initial studies have been carried out in patients using monocyte chemoattractant protein-1 (MCP-1) inhibitors. This review summarizes the known function of MCP-1 in regulating monocytes during inflammation and its role in inflammatory disease of the kidney.

Recent findings: MCP-1 is one of the first chemokines described and plays an important role in renal inflammatory disease. The function of MCP-1 has been investigated and analyzed in both animal models of renal disease and renal patients. MCP-1 mediates firstly the release of monocytes from the bone marrow, and then generates a gradient in the endothelial glycocalyx to direct monocytes to sites of inflammation, thereby alleviating the migration of blood leukocytes into the inflamed tissue. In addition, MCP-1 has direct signaling effects in monocytes and influences migration, proliferation, and differentiation of leukocytes. Blockade of MCP-1 in several models of renal disease has ameliorated the disease, suggesting that inhibition of MCP-1 is a promising and valid strategy to treat patients with renal inflammatory disease.

Summary: Understanding the role of MCP-1 in monocyte homeostasis and the implications of MCP-1 inhibition in renal disease will help in designing better diagnostic and therapeutic strategies in patients with inflammatory renal disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Movement
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / physiology*
  • Diabetic Nephropathies / etiology
  • Humans
  • Kidney / physiology
  • Kidney Diseases / etiology*
  • Monocytes / physiology
  • Nephritis / etiology
  • Vasculitis / etiology


  • CCL2 protein, human
  • Chemokine CCL2